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sis is reported with increasing frequency. Controversy
still exists concerning the optimum management of
aspergilloma.3 With the widespread use of chemother-
apy, invasive pulmonary aspergillosis is increasingly
reported, occurring in up to 20% of patients who
undergo treatment of acute leukemia.4 High morbidity
and mortality rates have been reported from surgical
series.5,6 Some authors have advocated the prophylac-
tic resection of all pulmonary aspergillomas (PA)
because of the risk of massive hemoptysis.6-8 Other
authors recommend surgical treatment only after
hemoptysis has occurred.9,10 A proportion of the
patient population will have advanced chronic lung
disease to a degree that eliminates the surgical option.
Some authors consider that surgical resection should
be avoided because of the high incidence of postoper-
ative complications.11 In this study we review the
results for all patients who underwent surgical man-
agement of PA at the Department of Thoracic Vascular
Surgery and Heart-Lung Transplantation at Marie-
Lannelongue Hospital over a 39-year period.
Since the original pathologic description of humanaspergillosis, by Virchow1 in 1856, the most
unusual form of Aspergillus infection recognized is
aspergilloma. Hinson and colleagues2 have classified
pulmonary aspergillosis into allergic, invasive (rarely
of surgical concern), and saprophytic infections,
which colonize preexisting lung cavities and produce
a fungus ball, or aspergilloma. Pulmonary aspergillo-
Objective: This retrospective study was designed to confirm that aggressive
pulmonary resection can provide effective long-term palliation of disease for
patients with pulmonary aspergilloma. 
Methods and results: From 1959 to 1998, 84 patients underwent a total of 90
operations for treatment of pulmonary aspergilloma in the Marie-
Lannelongue Hospital. The mean follow-up period was 9 years, and 83% of
the patients were followed up for 5 years or until death, if the latter occurred
earlier. The median age was 44 years. The most common indications were
hemoptysis (66%) and sputum production (15%). Fifteen patients (18%) had
no symptoms. Tuberculosis and lung abscess were the most common under-
lying causes of lung disease (65%). The procedures were 70 lobar or seg-
mental resections, 8 cavernostomies, and 7 pneumonectomies. Five thora-
coplasties were required after lobectomy (3 patients) or pneumonectomy (2
patients). The operative mortality rate was 4%. The major complications
were bleeding (23 patients), prolonged air leak (31 patients), respiratory fail-
ure (10 patients), and empyema (5 patients). The actuarial survival curve
showed 84% survival at 5 years and 74% survival at 10 years. During the
first 2 years, death was related to the surgical procedure and the underlying
disease. In contrast, 85% of the survivors had a good late result. 
Conclusion: Lobar resection in both the symptomatic and the asymptomatic
patients was conducted in low-risk settings. For patients whose condition is
unfit for pulmonary resection, cavernostomy may need to be undertaken
despite the high operative risk. The better survival rate in this study may have
been due to the selection of patients with better lung function and localized
pulmonary disease. (J Thorac Cardiovasc Surg 2000;119:906-12)
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Patients and methods
Patient population.  Eighty-four patients with PA were
evaluated and treated at Marie-Lannelongue Hospital
between 1959 and 1998. The group consisted of 63 men and
21 women, with an average age of 44 ± 13 years.
The records of those 84 patients were reviewed for
immunologic risk factors, preoperative signs and symptoms,
preoperative chest radiography findings, indications for
surgery, surgical procedures performed, postoperative com-
plications, and long-term follow-up status. All the survival
probabilities were calculated by the Kaplan-Meier method
and plotted at annual intervals, with the day of surgery as the
starting time. Operative death and death from all causes were
included in the survival statistics. Analysis of the patient pop-
ulation included classic variables (eg: age, symptoms, chest
radiograph, computed tomography [CT] scan) and some spe-
cific variables, such as respiratory function (percentage vital
capacity and forced expiratory volume in 1 second/forced
vital capacity) and serodiagnosis (number of precipitations on
immunodiffusion tests). Operative death was defined as any
death occurring during the first 30-day period or during the
initial hospital stay. Bleeding was considered excessive when
the sum of preoperative bleeding plus postoperative drainage
over the first 24 hours exceeded 1500 mL. Pleural space prob-
lems included air leaks prolonged beyond 10 days. The com-
parisons were conducted with the χ2 test.
Hemoptysis, the most frequent symptom, occurred in 56
patients (66%). The degree of hemoptysis was categorized
by the amount of blood lost in 24 hours. Hemoptysis was
considered massive if the amount was more than 300 mL,
severe if between 150 and 300 mL, and moderate if less than
150 mL. Hemoptysis was massive in 11 patients, severe in
19 patients, and moderate in 26 patients. Chronic cough and
copious sputum production were the primary symptoms in
13 patients (15% ± 7%). Fifteen patients (18% ± 8%) were
asymptomatic (Table I). Concomitant pulmonary diseases
were frequent (Table II). Tuberculosis occurred in 44
patients (60%); lung abscess occurred in 11 patients (13%);
primary chronic obstructive airways disease was present in
5 patients (6%), and 4 patients (4%) had an underlying
hematologic disease, such Hodgkin’s lymphoma or acute
lymphoblastic leukemia. PA was diagnosed in each patient
by one or more methods. The diagnosis was initially sus-
pected in all patients on the basis of the chest radiograph
findings. The methods also included bronchoscopy with
bronchoalveolar lavage, immunodiffusion tests, and chest
CT scans. Sputum or bronchoscopic aspirate cultures were
repeatedly positive for Aspergillus fumigatus in 27 patients
(32%). Immunodiffusion tests detected precipitins in 66
patients (78%). All the patients in this series had radio-
graphic findings of acute or chronic pulmonary disease
with cavities (Table III). Tomography and, more recently,
CT scans confirmed the classic picture of an intracavitary
mass surrounded by a crescent of air. The cavities were sit-
uated in the upper lobes (60 patients) or superior segment
of the lower lobe. Cavities were present bilaterally in 2
patients. The maximum diameter varied from 1.5 to 9 cm
(mean, 4 cm). The mean ratio of forced expiratory volume
to vital capacity was 72 for the lobectomy group, 63 for the
pneumonectomy group, and 58 for the cavernostomy group
(P < .01). Mean vital capacity (expressed as a percentage of
the normal values for the sex, age, and weight) was 90 ± 12
for the lobectomy, 65 ± 17 for the pneumonectomy, and 56
± 16 for the cavernostomy group (P < .01). Preoperative
pulmonary function tests showed a mean forced expiratory
volume in 1 second/forced vital capacity of 2.01/2.60.
Operative procedures.  The operative procedures, shown
in Table IV, included 70 lobar or segmental resections, 7
pneumonectomies, 8 cavernostomies, and 5 thoracoplasties
(subsequent to lobar resections or pneumonectomies).
Table I. Symptoms in 84 patients with PA
Symptom n
Cough 13
Hemoptysis
Minor 54
Major 2
Fever 6
Weight loss 2
Sputum 13
Chest pain 2
Asymptomatic 15
Table II. Underlying lung disorders in 84 patients
with PA
Disorder n
Normal lung 9
Mycobacterium 44
Bullae, bleb 5
Chronic infection 11
Acute infection (sporotrichosis) 2
Malignant lesions 1
Sarcoidosis 1
Table III. Chest radiograph or CT scan findings and
location of PA in 84 patients
n
Radiologic and CT scan findings
Cavity 38
Mass 35
Infiltrate 7
Emphysema 4
Location
Right upper lobe 36
Right middle lobe 4
Right lower lobe 2
Left upper lobe 24
Left lower lobe 3
Multiple locations 1
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Lobectomy and segmentectomy were the most frequent ini-
tial procedures for PA. Wedge excision6 was required in
patients with either small peripheral lesions or poor respira-
tory functional reserve. Cavernostomy8 was performed under
local or regional anesthesia through a 5-cm incision overly-
ing the aspergilloma cavity, guided by echography. The cavi-
ty was then incised, and the fungus ball was removed and sent
to a pathologist. A short segment of the overlying rib was
then excised before the insertion of 2 chest drains. All
patients with cavernostomy underwent daily dressing
changes and local instillation of amphotericin B. To minimize
the risk of postoperative complications, the ipsilateral latis-
simus dorsi muscle was mobilized from its distal attachment,
tunneled, and fixed into the residual cavity (in the presence of
the plastic surgeon) in the case of atrophy of the extrathoracic
skeletal muscle. This care was continued for 2 to 6 months,
followed by closure with a muscle flap in 4 patients.
Cavernostomy alone is usually proposed to the most chal-
lenging group of patients, including those patients with
severe hemoptysis who have had severe lung destruction
associated with a prohibitive risk of morbidity (Fig 1).
Aspergillus was histologically confirmed on all resected
specimens.
Follow-up.  A bronchopleural fistula with persistent air
space developed in 5 patients (after lobectomy [3 patients]
and after pneumonectomy [2 patients]). Thoracoplasty was
required in all 5 patients. During follow-up, there were 13
late deaths and 7 deaths from respiratory disease other than
aspergilloma (3 deaths from acute pneumonia and 4 deaths
from chronic respiratory insufficiency). Four patients died of
nonrespiratory causes (myocardial infarction, stroke, lung
cancer), and 2 patients died of unknown reasons (Table V).
No patient died of aspergillosis. One patient had more than 1
aspergilloma. The interval between the first and the second
aspergilloma, as asserted by reviewing chest radiographs,
was 3 years. The first aspergilloma was resected with lobec-
tomy, followed by thoracoplasty 5 months later, and the sec-
ond aspergilloma was treated with ipsilateral pneumonecto-
my. This patient is free of symptoms. Cavernostomy was
performed in 8 patients for whom pulmonary resection was
considered too dangerous because of their extensive lung dis-
ease and poor pulmonary function (mean vital capacity, 56 ±
16 vs 90 ± 12 in the lobectomy group; P < .01). One patient
died of pneumonia after cavernostomy. Another patient died
of respiratory insufficiency that occurred 5 years after the
resection of a chronically suppurating upper lobe. The 6 other
patients are currently alive.
Results
One preoperative death, from massive preoperative
bleeding, occurred early in the center’s experience
(1960), and 3 other deaths occurred after the opera-
tion. One patient died of underlying disease (hemopa-
thy) 8 days after lobectomy, and 2 patients’ deaths in
the postoperative course were related to severe bron-
chopulmonary infections and respiratory failure
(Table V). Fifty-eight patients had 69 nonfatal com-
plications (Table VI). Postoperative hospital stay
exceeded 30 days for 16 patients. Major blood loss
was noted in 23 patients, and pleural space problems
existed in 31 patients. Thoracoplasty was required in
5 patients. Ten patients experienced respiratory dis-
tress, 5 of whom needed tracheotomy for long-term
respiratory assistance.
The perioperative mortality rate was 4%. The most
common preexisting lung lesion was an open-healed
tuberculous cavity in 44 patients (52%). Other common
lesions were other forms of upper-lobe fibrosis, sar-
coidosis, and allergic bronchopulmonary aspergillosis.
Eleven patients had fibrotic or cavitary disease for
which no cause was found, and 9 patients had no
known previous lung disease. Seventy patients (83%)
were followed up for a minimum of 6 years unless
death occurred; 31 patients were followed up for 10
years or more. Three patients were lost to follow-up
immediately after discharge, and 5 patients were lost to
follow-up after a mean period of 5 years. The actuarial
Table IV. Surgical procedures performed in 84
patients with PA
Procedure n
Initial
Lobectomy 46
Segmentectomy 18
Wedge excision 6
Pneumonectomy 6
Cavernostomy 8
Subsequent
Thoracoplasty 5
Pneumonectomy 1
Fig 1. A CT scan of a PA, with surrounding destroyed lung
tissue in a patient with previous thoracoplasty.
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survival curve (Fig 2) for 84 patients showed 84% sur-
vival at 5 years, 74% at 10 years, and 67% at 15 years.
Comments
When Aspergillus colonizes a preexisting cavity,
the result is a fungus ball or mycetoma that consists
of branched, septate hyphae, and blood cells.
McPherson12 estimated the prevalence of aspergillo-
ma at 0.01%, based on a 10-year survey of chest
radiographs in a population of 60,000 patients. A
British cooperative study found that patients with a
history of tuberculosis and thick-walled lung cavities
of more than a 7-year duration had a higher risk of
aspergilloma.13
From 1959 to 1992, the most common preexisting
condition was tuberculosis. Since that date, the preva-
lence of PA has slightly decreased. Sixty-three patients
underwent operation between 1959 and 1992, whereas
only 21 patients underwent operation in the last 6 years.
This decrease seems to be related to the regression of
the prevalence of sequelae of pulmonary tuberculosis
and the extensive use of new antifungal agents.14-16
The clinical picture of aspergilloma ranges from an
incidental radiologic finding to life-threatening
hemoptysis. The survey of the patients spans 39 years.
During that time different physicians managed appar-
ently similar cases in different ways. We have con-
firmed that the upper lobes are the predominant sites of
aspergillomas. The size of the aspergillomas was vari-
able and bore no relation to the severity of hemoptysis.
Fifteen patients (18%) were asymptomatic, like those
in the series published by Jewkes and colleagues,17 in
which 22% of the patients were symptom free. This
may be explained by the fact that our series is confined
to patients who were admitted to a university hospital
and therefore consists of more severely affected
patients who were referred by the Department of Chest
Medicine for a surgical option. The natural history of
aspergilloma is not well documented. Few long-term
follow-up reports have been published, and in many of
the reports, it is difficult to distinguish between the
course of the underlying disease and that of the
aspergilloma.18-21 A definitive diagnosis of aspergillo-
ma is usually established by the characteristic appear-
ance of a fungus ball on chest radiograph, tomograph,
or CT scan (Fig 2). Although CT scan is thought to be
more effective in the diagnosis of incipient disease,22
we observed no advantage over the more classic tomo-
graphs. Isolated growth of Aspergillus from sputum
culture is not diagnostic, but positive sputum cultures
have repeatedly had more significance. Twenty-seven
patients (32%) repeatedly had positive sputum cultures
for Aspergillus. The serum test for precipitins has been
found to be both a sensitive and specific method for
detecting antibodies to A fumigatus.5 Immunodiffusion
tests detected precipitins in 66 patients (78%). In the
event of recent chest radiograph modifications such as
infiltration, cavitation, and cyst formation in patients
with chronic lung disease, the patients should be
screened for Aspergillus infection with the use of
immunodiffusion tests. It would appear that the risk of
an aspergilloma causing the hematogenous spread of
the fungus is negligible.23 The definitive diagnosis of
aspergilloma is established by demonstrating and cul-
turing the organism from the resected specimen.
Pulmonary aspergillosis, particularly the intracavi-
tary type, can cause sudden and massive hemoptysis. In
reported series,5,16,21 the incidence of hemoptysis in
patients with an aspergilloma has ranged from 50% to
83% and is severe or recurrent in 10%.21 Bleeding clas-
sically occurs from bronchial arteries and usually stops
spontaneously. Several mechanisms for the hemoptysis
have been proposed included erosion of the vascular
cyst wall by motion of the mycetoma, elaboration of
endotoxin by the fungus, and the patient’s underlying
disease.7 Some of these patients experienced massive
bleeding; the first hemoptysis is often fatal. The reason
for this is unclear. Young and colleagues16 postulate
that bleeding in these cases may be from intercostal
arteries. Extension of the mycotic process with
parenchymal destruction at the periphery of the lung
invading the adjacent chest wall may lead to erosion of
the intercostal arteries. Bleeding from such large arter-
ies is unlikely to stop spontaneously. Neither the size,
the complexity of the lesion, the presence of a warning
minor hemoptysis, nor the type of underlying disease
can predict those patients who will progress to life-
threatening hemoptysis.17 Systemic antifungal agents
(given orally or intravenously or by inhalation or direct
instillation into the cavity), which have been shown to
be effective in superficial infections and in some sys-
temic fungal infections, have shown no consistent suc-
cess in alleviating symptoms or treating the disease
process.21 Several studies21,24 have shown that antifun-
Table V. Deaths in 84 patients with PA
Causes of death n
Respiratory disease other than aspergilloma 7
Acute pneumonia 3
Chronic respiratory insufficiency 4
After surgery for aspergilloma 4
Nonrespiratory causes (eg, myocardial infarction, stroke) 4
Unknown 2
Total deaths 17
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gal treatment varies considerably from case to case and
does not affect the size of the aspergilloma or death. In
our series, 9 patients with PA had been unsuccessfully
treated with antifungal therapy and were referred for
surgical management. Bronchial artery embolization
has been largely unsuccessful because of difficulty in
identifying the bleeding artery.
The main goal of the surgical procedure is to resect
cavitations near the pulmonary vessels to prevent fatal
hemoptysis although limiting the parenchymal resection
as much as possible not to impair lung function. There is
no general agreement on the management of PA. Gerstl
and colleagues25 reported successful lobectomy for pul-
monary aspergillosis in 1948. Since then, surgical resec-
tion has become widely accepted as the treatment of
choice for intracavitary mycetoma (fungus balls).
Lobectomy is the preferred procedure, but PA have been
removed by segmentectomy. Pneumonectomy is required
in widespread disease or multiple unilateral aspergilloma
and should be performed when there is substantial diffuse
infiltration surrounding destroyed lung tissue (ie, from
previous tuberculosis) and when there was also an asso-
ciated fungus ball in one of the involved lobes.20
Extension of the aspergilloma and the underlying pul-
monary disease should be considered. The high risk of
pneumonectomy for aspergilloma is primarily due to the
associated technical difficulties that are the result of the
often obliterated pleural space and indurated hilar struc-
tures. In patients with an invasive or pyogenic compo-
nent, there exists the possibility of postoperative bron-
chopleural fistula and empyema. It could be helpful to
cover the resected bronchus with a pericardial, pleural, or
omental flap. These surgical techniques have been pro-
posed in the last patients who have undergone operations
since 1998. The effort always is made to conserve lung
tissue because most of these patients have diminished
pulmonary reserve.
With the improvement of the surgical techniques
(assiduous techniques to reduce both air leaks and
postoperative hemorrhage), aggressive surgery6
offers, even in asymptomatic patients, 4 potential
benefits: prevention of hemoptysis, eradication of the
pyogenic component, limitation of the symptoms as
the result of invasive aspergillosis or increased growth
of the mycetoma, and prolongation of life. Several
authors5,6,22 insisted that all good-risk patients, even if
asymptomatic, should undergo lung resection to avoid
the possibility of exsanguinating hemorrhage. How-
ever, PA is essentially a benign disease, so the risk of
early postoperative death should be completely avoid-
able. This experience associated with an extremely
low morbidity rate has led to our present policy of
advocating prophylactic resection whenever a fungus
ball is diagnosed if the patient is a suitable candidate
for operation. The overall postoperative mortality rate
in our series was 4%, similar to that reported by oth-
ers such as Garvey and colleagues5 (9%), Massard
and colleagues6 (9.5%), Daly and colleagues10 (5% in
simple aspergilloma, 34% in complex aspergilloma),
and Karas and colleagues11 (13%). Pleural space
problems were the most common postoperative inci-
dents in our series (31 patients; 35%). In our study
until 1992, the measures used to prevent prolonged air
leak, particularly after upper lobectomy, consisted in
apical pleural tenting. In the last years, with the
exception of the application of staple reinforcement
materials, including expanding polytetrafluoroethyl-
ene sleeves, we used fibrin glue, which has been
shown to be an effective sealant for pulmonary
parenchymal defects.
We agree with Massard and colleagues6 that thora-
coplasty may be indicated subsequent to lobectomy.
In our series, 5 thoracoplasties were performed as a
second choice procedure after lobectomy (3 patients)
Table VI. Postoperative outcome and the surgical technique
Lobectomy† Pneumonectomy Cavernostomy Thoracoplasty
Variable (n = 70) (n = 7) (n = 8) (n = 5)
Death 2 1 1
Prolonged air leak 27 — 4 —
Hemorrhage 19 3 1 —
Empyema 3 2 —
Respiratory problem 5 2 2 1
Hospital stay > 30 d 4 2 5 5
Vital capacity* 90 ± 12.2 65 ± 17.8 56.3 ± 16.2 60.1 ± 14.1
FEV/VC 72.6 ± 1.8 63.5 ± 2.0 58.5 ± 1.5 56.8 ± 1.0
FEV, Forced expiratory volume in 1 second (P < .01); VC, vital capacity.
*Percentage of the normal values (mean ± SD; P < .01).
†Wedges and segmentectomies included.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 5
Babatasi et al 911
or pneumonectomy (2 patients) for bronchopleural
fistula or empyema. The outcome after thoracoplasty
was good with no deaths, and only 1 patient had res-
piratory insufficiency. Postoperative bleeding is also
a common complication. In the second period (1992-
1998), the incidence of bleeding decreased from 30%
to 7%. This decrease is probably related to the regres-
sion of the prevalence of severe long-term sequelae to
pulmonary tuberculosis.18 There remains a subgroup
of patients whose general medical condition or pul-
monary function mitigates against resection. To
reduce operative complications in patients in poor
general condition and if the aspergilloma is located
peripherally, an alternative approach consists in cav-
ernostomy and the obliteration of the cavity with
intrathoracic transposition of extrathoracic skeletal
muscle. This was conducted in 4 of 8 patients who
underwent operation, with good long-term results.
Further studies are necessary to substantiate these
encouraging results. Pulmonary resection should be
performed in patients with PA with a low risk and
with a strong likelihood of long-term cure. Shirakusa
and colleagues22 wrote that, because of the sapro-
phytic character of the organism, it is desirable to
limit the resection as much as possible, so as not to
decrease lung function. Their analysis was based on
the age distribution observed in aspergilloma reports
from 10 to 20 years previously.5,10 In conclusion, in
the light of our experience and the recent litera-
ture,6,7,14,18 we advise pulmonary resection whenever
the diagnosis of mycetoma is confirmed and the
patient is a suitable candidate for operation. In a few
cases, resection may require subsequent thoracoplas-
ty to prevent space problems and the possible devel-
opment of empyema.
We thank Remy Morello, MD, biostatistician, Department
of Biostatistics and Medical Information, for his statistical
assistance.
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